Through a RNAi synthetic lethal screen we have identified the protein SUMOylation pathway to be required for the viability of Ras mutant cancer cells. PURPOSE In this project we aim to address the following questions: 1. the mechanism by which the inhibition of SUMOylation pathway is synthetically lethal with Ras mutation;2. which cellular proteins are differentially SUMOylated in Ras mutant cells;3. How the changes in SUMOylation status in these cells affect their function in the context of Ras mutation SIGNIFICANT MATERIALS AND METHODS 1. shRNAs that target the SUMO E1 and E2 ligases. 2. Stable cell lines that express 6x His tagged proteins. 3. mass-spectrometry protocol for protein ID FY2010 ACCOMPLISHMENT We have validated shRNAs that target the SUMO E1 and E2 ligases. We have also generated cell lines stably expressing His-tagged SUMO1 or SUMO2 proteins. We have carried out a proteomics screen and identified a number of candidate proteins that are differentially SUMOylated between Ras WT and mutant cells.
| Zhang, Haibo; Luo, Ji (2016) SUMO wrestling with Ras. Small GTPases 7:39-46 |
| Ma, Chi; Kesarwala, Aparna H; Eggert, Tobias et al. (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:253-7 |
| Yu, Bing; Swatkoski, Stephen; Holly, Alesia et al. (2015) Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci U S A 112:E1724-33 |
| Kessler, Jessica D; Kahle, Kristopher T; Sun, Tingting et al. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335:348-53 |
| Weng, Meng-Tzu; Lee, Jih-Hsiang; Wei, Shu-Chen et al. (2012) Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A 109:E3659-67 |
